Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

147.50
-1.5500-1.04%
Pre-market: 148.250.7500+0.51%08:18 EDT
Volume:4.44M
Turnover:655.84M
Market Cap:183.00B
PE:-56.41
High:149.44
Open:149.44
Low:147.19
Close:149.05
52wk High:157.29
52wk Low:108.46
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.85
T/O Rate:0.36%
Dividend:3.22
Dividend Rate:2.18%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.47
PE(LYR):21.76

Loading ...

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 23

Moderna Inc. Stock Climbs 12.3%, Outperforms Peers

Dow Jones
·
Sep 22

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 18

Moderna Inc. Stock Climbs 8.5%, Outperforms Peers

Dow Jones
·
Sep 18

Gilead Chief Communications and Corporate Affairs Officer Johanna Mercier Sells USD 431,819 of Common Stock

Reuters
·
Sep 17

Gilead - Expands Six Royalty-Free Voluntary Licensing Agreements for Once-Yearly Lenacapavir for Hiv Prevention

THOMSON REUTERS
·
Sep 16

The 'CIA' Strategy Beating the Market: How One Top-Performing Money Manager Spots Mispriced Stocks.

Dow Jones
·
Sep 16

Rohto Starts Phase II Trial of RE-01 Cell Therapy for Refractory Ischemic Leg Ulcers

Reuters
·
Sep 16

Gilead Sciences Expands Lenacapavir Access to 14 Countries

MT Newswires Live
·
Sep 15

Gilead announces agreement with PAHO for lenacapavir access

TIPRANKS
·
Sep 15

Gilead: Explores Opportunities with Brazilian Health Ministry to Advance Ministry’s Goal of Enabling Local Production of Lenacapavir

THOMSON REUTERS
·
Sep 15

Gilead: Agreement Establishes Regional Pathway Through Pan American Health Organization's Regional Revolving Funds

THOMSON REUTERS
·
Sep 15

Gilead: Co & Paho Announce Partnership to Accelerate Access to Twice-Yearly Lenacapavir for Hiv Prevention Across Latin America & Caribbean

THOMSON REUTERS
·
Sep 15

Gilead, PAHO Agree on HIV Prevention Drug Access in Latin America, Caribbean

Reuters
·
Sep 15

Gilead: to Continue Exploring Opportunities to Work with Paho to Support Country Readiness & Scale-up of Long-Acting Hiv Prevention Access

THOMSON REUTERS
·
Sep 15

Gilead Exec Says Weekly Oral Hiv Prevention Drug Expected to Launch in First Quarter of 2027 - Conf Call

THOMSON REUTERS
·
Sep 15

Gilead Exec Says Hiv Market Growth Should Normalize to 2%-3% Within Next Couple of Quarters - Conf Call

THOMSON REUTERS
·
Sep 15

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 15

Moderna Inc. Stock Rallies 5.4%, Outperforms Peers

Dow Jones
·
Sep 12

RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)

TIPRANKS
·
Sep 11